Date of Abstract presentation9th December 2023IndicationsLarge B-cell lymphoma (LBCL)Abstract Number105Abstract typeOral
For those patients with large B-cell lymphoma (LBCL) who remain uncured following initial treatment, the conventional approach for second-line therapy has been the utilization of high-dose chemotherapy (HDCT) and hematopoietic stem cell transplantation (HSCT). The PILOT study included 61 patients with relapsed or refractory LBCL who met at least one criterion that made them not eligible for transplant. According to the findings presented at the ASH 2023, the overall response rate (ORR) was 80%, with 54% of patients achieving a complete response (...
